Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited, a biopharmaceutical company, has reported progress with the FDA on their cellular medicines, signaling potential approvals for treatments in acute graft versus host disease in children and chronic heart failure in adults. They are preparing to resubmit a Biologics License Application for remestemcel-L and seeking an accelerated approval pathway for rexlemestrocel-L. The company also strengthened its financial position with A$97 million raised and a focus on cost containment, resulting in a reduced net operating cash spend.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
